25 Aug 2026 Cost-effectiveness of triplet therapy for BRAF V600E-mutated metastatic CRC in China Skip to content The CRC Digest Cost-effectiveness of triplet therapy for BRAF V600E-mutated metastatic CRC in China (Frontiers in Pharmacology)